331 related articles for article (PubMed ID: 24522479)
1. Src signaling pathways in prostate cancer.
Varkaris A; Katsiampoura AD; Araujo JC; Gallick GE; Corn PG
Cancer Metastasis Rev; 2014 Sep; 33(2-3):595-606. PubMed ID: 24522479
[TBL] [Abstract][Full Text] [Related]
2. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
3. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.
Sicoli D; Jiao X; Ju X; Velasco-Velazquez M; Ertel A; Addya S; Li Z; Andò S; Fatatis A; Paudyal B; Cristofanilli M; Thakur ML; Lisanti MP; Pestell RG
Cancer Res; 2014 Dec; 74(23):7103-14. PubMed ID: 25452256
[TBL] [Abstract][Full Text] [Related]
4. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Cai H; Babic I; Wei X; Huang J; Witte ON
Cancer Res; 2011 Feb; 71(3):862-72. PubMed ID: 21135112
[TBL] [Abstract][Full Text] [Related]
5. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
6. Differential transformation capacity of Src family kinases during the initiation of prostate cancer.
Cai H; Smith DA; Memarzadeh S; Lowell CA; Cooper JA; Witte ON
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6579-84. PubMed ID: 21464326
[TBL] [Abstract][Full Text] [Related]
7. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
8. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
11. Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice.
Kim S; Yang X; Li Q; Wu M; Costyn L; Beharry Z; Bartlett MG; Cai H
J Biol Chem; 2017 Nov; 292(45):18422-18433. PubMed ID: 28939770
[TBL] [Abstract][Full Text] [Related]
12. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Goel RK; Lukong KE
Cancer Metastasis Rev; 2016 Jun; 35(2):179-99. PubMed ID: 27067725
[TBL] [Abstract][Full Text] [Related]
13. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
14. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
15. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
16. Src kinases as therapeutic targets for cancer.
Kim LC; Song L; Haura EB
Nat Rev Clin Oncol; 2009 Oct; 6(10):587-95. PubMed ID: 19787002
[TBL] [Abstract][Full Text] [Related]
17. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
18. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
19. CX3CL1/fractalkine enhances prostate cancer spinal metastasis by activating the Src/FAK pathway.
Liu P; Liang Y; Jiang L; Wang H; Wang S; Dong J
Int J Oncol; 2018 Oct; 53(4):1544-1556. PubMed ID: 30066854
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
